Mannitol use in acute stroke: Case fatality at 30 days and 1 year

Stroke

Volumn 34, Issue 7, 2003, Pages 1730-1735

  Bereczki, Dániel ^a,d   Mihálka, László ^b   Szatmári, Szabolcs ^c   Fekete, Klára ^a   Di Cesar, David ^a   Fülesdi, Béla ^a   Csiba, László ^a   Fekete, István ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UZHGOROD NATIONAL UNIVERSITY   (Ukraine)

^c UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Acute; Mannitol; Mortality; Stroke; Stroke management

Indexed keywords

ACETYLSALICYLIC ACID; MANNITOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FATALITY; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; STROKE; SURVIVAL; TREATMENT OUTCOME; TREATMENT PLANNING;

ACUTE DISEASE; AGED; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DATABASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; LOGISTIC MODELS; MALE; MANNITOL; MIDDLE AGED; ODDS RATIO; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037493247     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000078658.52316.E8     Document Type: Article

References (18)

1. Famularo G. The puzzle of neuronal death and life: is mannitol the right drug for the treatment of brain edema associated with ischemic stroke? Eur J Emerg Med. 1999;6:363-368.
2. Videen TO, Zazulia AR, Manno EM, Derdeyn CP, Adams RE, Diringer MN, Powers WJ. Mannitol bolus preferentially shrinks non-infarcted brain in patients with ischemic stroke. Neurology. 2001;57:2120-2122.
3. Mano EM, Adams RE, Derdeyn CP, Powers WJ, Diringer MN. The effects of mannitol on cerebral edema after large hemispheric cerebral infarct. Neurology. 1999;52:583-587.
4. Schwarz S, Schwab S, Bertram M, Aschoff A, Hacke W. Effects of hypertonic saline hydroxyethyl starch solution and mannitol in patients with increased intracranial pressure after stroke. Stroke. 1998;29:1550-1555.
5. Steiner T, Pilz J, Schellinger P, Wirtz R, Friederichs V, Aschoff A, Hacke W. Multimodal online monitoring in middle cerebral artery territory stroke. Stroke. 2001;32:2500-2506.
6. Candelise L, Colombo A, Spinnler H. Therapy against brain swelling in stroke patients: a retrospective clinical study on 227 patients. Stroke. 1975;6:353-356.
7. Santambrogio S, Martinotti R, Sardella F, Porro F, Randazzo A. Is there a real treatment for stroke? clinical and statistical comparison of different treatments in 300 patients. Stroke. 1978;9:130-132.
8. Bereczki D, Liu M, do Prado GF, Fekete I. Cochrane report: a systematic review of mannitol therapy for acute ischemic stroke and cerebral parenchymal hemorrhage. Stroke. 2000;31:2719-2722.
9. Adams HP, Brott TG, Crowell RM, et al. Guidelines for the management of patients with acute ischemic stroke: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 1994;25:1901-1914.
10. Hacke W, Kaste M, Skyhoj-Olsen T, Orgogozo JM, Bogousslavsky J. European Stroke Initiative (EUSI) recommendations for stroke management: the European Stroke Initiative Writing Committee. Eur J Neurol. 2000;7:607-623.
11. Bereczki D, Mihálka L, Szatmári S, Di Cesar D, Fülesdi B, Csiba L, Fekete I. Mannitol use and outcome in acute stroke: results from the Mures-Uzhgorod-Debrecen study. Eur J Neurol. 2002;9(suppl 2):173. Abstract.
12. Szatmári S, Pascu I, Mihálka L, et al. The Mureş-Uzhgorod-Debrecen (MUD) study: a comparison of hospital stroke services in Central-Eastern Europe. Eur J Neurol. 2002;9:293-296.
13. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in ischemic stroke. Stroke. 1985;16:885-890.
14. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet. 1997;349:1569-1581.
15. MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet. 2001;357:455-462.
16. Howard G, Walker MD, Becker C, Coull B, Feibel J, McLeroy K, Toole JF, Yatsu F. Community hospital-based stroke programs: North Carolina, Oregon, and New York, III: factors influencing survival after stroke: proportional hazards analysis of 4219 patients. Stroke. 1986;17:294-299.
17. Lampl Y, Gilad R, Eshel Y, Sarova-Pinhas I. Neurological and functional outcome in patients with supratentorial hemorrhages: a prospective study. Stroke. 1995;26:2249-2253.
18. Wardlaw JM, Lewis SC, Dennis MS, Counsell C, McDowall M. Is visible infarction on computed tomography associated with an adverse prognosis in acute ischemic stroke? Stroke. 1998;29:1315-1319.